161 related articles for article (PubMed ID: 1420819)
1. The present status of tissue factor pathway inhibitor.
Lindahl AK; Sandset PM; Abildgaard U
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):439-49. PubMed ID: 1420819
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
3. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor pathway inhibitor: proposed heparin recognition region.
Harenberg J; Malsch R; Heene DL
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S50-6. PubMed ID: 7647222
[TBL] [Abstract][Full Text] [Related]
5. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
[TBL] [Abstract][Full Text] [Related]
6. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
[TBL] [Abstract][Full Text] [Related]
7. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
Alban S; Gastpar R
Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
[TBL] [Abstract][Full Text] [Related]
10. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
Shimura M; Wada H; Wakita Y; Nakase T; Hiyoyama K; Nagaya S; Mori Y; Shiku H
Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
[TBL] [Abstract][Full Text] [Related]
11. The role of tissue factor pathway inhibitor in tumor growth and metastasis.
Amirkhosravi A; Meyer T; Amaya M; Davila M; Mousa SA; Robson T; Francis JL
Semin Thromb Hemost; 2007 Oct; 33(7):643-52. PubMed ID: 18000790
[TBL] [Abstract][Full Text] [Related]
12. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration.
Cella G; Cipriani A; Tommasini A; Rampin E; Sbarai A; Rocconi R; Mazzaro G; Luzzatto G
Semin Thromb Hemost; 1997; 23(1):45-9. PubMed ID: 9156410
[TBL] [Abstract][Full Text] [Related]
13. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor pathway inhibitor (TFPI).
Rucińska M; Gacko M; Skrzydlewski Z
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():118-22. PubMed ID: 9337530
[TBL] [Abstract][Full Text] [Related]
15. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
Gori AM; Pepe G; Attanasio M; Falciani M; Abbate R; Prisco D; Fedi S; Giusti B; Brunelli T; Giusti B; Brunelli T; Comeglio P; Gensini GF; Neri Serneri GG
Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
17. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
18. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.
Alban S
Semin Thromb Hemost; 2001 Oct; 27(5):503-11. PubMed ID: 11668420
[TBL] [Abstract][Full Text] [Related]
19. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
Kristensen HI; Ostergaard PB; Nordfang O; Abildgaard U; Lindahl AK
Thromb Haemost; 1992 Sep; 68(3):310-4. PubMed ID: 1332210
[TBL] [Abstract][Full Text] [Related]
20. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
Ariëns RA; Alberio G; Moia M; Mannucci PM
Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
